Carmen Cheng
Overview
Explore the profile of Carmen Cheng including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
40
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kishk O, Kim I, Cheng C, Summan M, Munoz M
Pediatr Nephrol
. 2024 Mar;
39(8):2429-2433.
PMID: 38462547
Background: The objective of this report is to identify and characterize cases of fibrosing colonopathy, a rare and underrecognized adverse event, associated with cysteamine delayed-release (DR) in patients with nephropathic...
2.
Gallagher C, Siddiqui W, Arnold T, Cheng C, Su E, Zhao Q
J Phys Chem C Nanomater Interfaces
. 2024 Feb;
128(7):2876-2883.
PMID: 38414836
Single-atom catalysts (SACs) of embedding an active metal in nitrogen-doped graphene are emergent catalytic materials in various applications. The rational design of efficient SACs necessitates an electronic and mechanistic understanding...
3.
Konkel K, Burkhart K, Cheng C, Lee R, Michele T, Mentari E, et al.
Clin Toxicol (Phila)
. 2024 Jan;
61(12):1065-1067.
PMID: 38174554
No abstract available.
4.
Phan M, Cheng C, Dang V, Wu E, Munoz M
Ther Innov Regul Sci
. 2023 Jun;
57(5):1062-1073.
PMID: 37351842
Introduction: The Food and Drug Administration Adverse Event Reporting System (FAERS) is a database of adverse event (AE) and medication error reports for drugs and therapeutic biologics. Examining trends of...
5.
Mohamoud M, Cheng C, Ryan D, Kim I, Wu E, Munoz M, et al.
Clin Pharmacol Ther
. 2023 Apr;
113(6):1368-1377.
PMID: 37021630
The US Food and Drug Administration's (FDA's) routine postmarketing drug safety monitoring may lead to safety-related labeling changes for identified risks. Additionally, the Best Pharmaceuticals for Children Act (BPCA) and...
6.
Kim I, Goulding M, Tian F, Karami S, Pham T, Cheng C, et al.
Pediatrics
. 2022 Nov;
150(6).
PMID: 36377394
Background And Objectives: Adverse events (AE), including death, occur in children with benzonatate use. This study aims to understand recent trends in benzonatate exposure and clinical consequences in pediatric patients....
7.
Mohamoud M, Chen Q, Croteau D, Cheng C, Burkhart K, Volpe D, et al.
J Clin Psychopharmacol
. 2022 Apr;
42(3):238-246.
PMID: 35489029
Purpose/background: Acute hyperkinetic movement disorders have been reported with the concomitant use of attention-deficit/hyperactivity disorder (ADHD) stimulants and antipsychotics in children and adolescents. We analyzed postmarketing reports of suspected acute...
8.
Pham P, Cheng C, Wu E, Kim I, Zhang R, Ma Y, et al.
Pharmaceut Med
. 2021 Sep;
35(5):307-316.
PMID: 34476768
Introduction: Missing age presents a significant challenge when evaluating individual case safety reports (ICSRs) in the FDA Adverse Event Reporting System (FAERS). When age is missing in an ICSR's structured...
9.
Lardieri A, Cheng C, Jones S, MCCulley L
Clin Toxicol (Phila)
. 2020 Sep;
59(5):448-449.
PMID: 32960110
No abstract available.
10.
MCCulley L, Cheng C, Mentari E, Diak I, Michele T
Clin Toxicol (Phila)
. 2020 Aug;
59(4):355-356.
PMID: 32852232
No abstract available.